目的：探讨 Siewert Ⅱ、Ⅲ型胃食管结合部癌（AEG）的临床特点及人表皮生长因子受体2（HER2）、细胞S 期激酶相关蛋白2（SKP2）表达变化。方法选取 SiewertⅡ及Ⅲ型 AEG 患者206例，比较二者的临床特点；应用免疫组化方法检测其 HER2、...目的：探讨 Siewert Ⅱ、Ⅲ型胃食管结合部癌（AEG）的临床特点及人表皮生长因子受体2（HER2）、细胞S 期激酶相关蛋白2（SKP2）表达变化。方法选取 SiewertⅡ及Ⅲ型 AEG 患者206例，比较二者的临床特点；应用免疫组化方法检测其 HER2、SKP2表达情况，分析 SiewertⅡ、Ⅲ型 AEG 患者 HER2、SKP2阳性表达与临床病理参数的关系。结果两型 AEG 患者肿瘤大小、淋巴结转移、肿瘤分化程度和 TNM分期比较有统计学差异（P 均＜0．05）。SiewertⅡ型 AEG 患者 HER2、SKP2阳性表达率分别为32．9％、41．2％，SiewertⅢ型 AEG 患者 HER2、SKP2阳性表达率分别为36．3％、55．4％；两组 SKP2阳性表达率差异有统计学意义（P ＜0．05）。SiewertⅡ或Ⅲ型 AEG 患者中，肿瘤直径＜5 cm 与≥5 cm、浸润深度 T1～T2与 T3～T4、高～中分化与低分化、淋巴结转移 N0～N1与 N2～N3之间 HER2阳性表达率有统计学差异（P 均＜0．05）。结论 HER2、SKP2异常表达可促进 AEG 的发生发展， HER2、SKP2表达检测对 AEG 早期诊断及疗效判断有重要作用。展开更多
Epidermal growth factor receptor (EGFR) plays a critical role in proliferation, apoptosis, angiogenesis, invasiveness and distant metastasis of tumors. In this study, the tumor targeting properties of anti-EGFR monocl...Epidermal growth factor receptor (EGFR) plays a critical role in proliferation, apoptosis, angiogenesis, invasiveness and distant metastasis of tumors. In this study, the tumor targeting properties of anti-EGFR monoclonal antibody (mAb) LA22 in a colon cancer mouse model are evaluated. The results from flow cytometry assay and immunofluorescent staining clearly showed that HT-29 human colon cancer cells were EGFR positive, and the binding of mAb LA22 to the HT-29 cell surface was specific. The saturation binding experiment of 125I-LA22 to HT-29 cells revealed that LA22 possessed moderate affinity to EGFR with the Kd value calculated to be 3.28±0.76 nM. The in vivo γ imaging demonstrated the specific accumulation of 125I-LA22 in HT-29 tumor xenografts. The specific tumor targeting properties of mAb LA22 make it a good candidate for tumor targeted radioimmunotherapy of EGFR-positive tumors when it is labeled with therapeutic nuclides, such as 131I, 177Lu, or 90Y.展开更多
文摘目的：探讨 Siewert Ⅱ、Ⅲ型胃食管结合部癌（AEG）的临床特点及人表皮生长因子受体2（HER2）、细胞S 期激酶相关蛋白2（SKP2）表达变化。方法选取 SiewertⅡ及Ⅲ型 AEG 患者206例，比较二者的临床特点；应用免疫组化方法检测其 HER2、SKP2表达情况，分析 SiewertⅡ、Ⅲ型 AEG 患者 HER2、SKP2阳性表达与临床病理参数的关系。结果两型 AEG 患者肿瘤大小、淋巴结转移、肿瘤分化程度和 TNM分期比较有统计学差异（P 均＜0．05）。SiewertⅡ型 AEG 患者 HER2、SKP2阳性表达率分别为32．9％、41．2％，SiewertⅢ型 AEG 患者 HER2、SKP2阳性表达率分别为36．3％、55．4％；两组 SKP2阳性表达率差异有统计学意义（P ＜0．05）。SiewertⅡ或Ⅲ型 AEG 患者中，肿瘤直径＜5 cm 与≥5 cm、浸润深度 T1～T2与 T3～T4、高～中分化与低分化、淋巴结转移 N0～N1与 N2～N3之间 HER2阳性表达率有统计学差异（P 均＜0．05）。结论 HER2、SKP2异常表达可促进 AEG 的发生发展， HER2、SKP2表达检测对 AEG 早期诊断及疗效判断有重要作用。
基金Supported by grants from Chinese National "863" project (2007AA02Z467)NSF (30640067, 30870728)
文摘Epidermal growth factor receptor (EGFR) plays a critical role in proliferation, apoptosis, angiogenesis, invasiveness and distant metastasis of tumors. In this study, the tumor targeting properties of anti-EGFR monoclonal antibody (mAb) LA22 in a colon cancer mouse model are evaluated. The results from flow cytometry assay and immunofluorescent staining clearly showed that HT-29 human colon cancer cells were EGFR positive, and the binding of mAb LA22 to the HT-29 cell surface was specific. The saturation binding experiment of 125I-LA22 to HT-29 cells revealed that LA22 possessed moderate affinity to EGFR with the Kd value calculated to be 3.28±0.76 nM. The in vivo γ imaging demonstrated the specific accumulation of 125I-LA22 in HT-29 tumor xenografts. The specific tumor targeting properties of mAb LA22 make it a good candidate for tumor targeted radioimmunotherapy of EGFR-positive tumors when it is labeled with therapeutic nuclides, such as 131I, 177Lu, or 90Y.
